Clinical evaluation of cefotetan in the treatment of lower respiratory tract infections

Cefotetan, a new cephamycin antibiotic, was evaluated for the treatment of lower respiratory tract infections. Intravenous cefotetan (2 g every 12 h) was administered for 4 to 8 days (mean, 5.8 days) to 56 hospitalized adult patients. Of the 41 evaluable patients, the clinical response was satisfact...

Full description

Saved in:
Bibliographic Details
Published in:Journal of antimicrobial chemotherapy 1983, Vol.11 (suppl-A), p.233-236
Main Authors: Nolen, Thomas M., Phillips, H. L., Hall, H. J.
Format: Article
Language:English
Subjects:
Adult
Aged
Anti-Bacterial Agents - therapeutic use
Cefotetan
Cephalosporins - therapeutic use
Cephamycins - therapeutic use
Female
Humans
Male
Middle Aged
Respiratory Tract Infections - drug therapy
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Cefotetan, a new cephamycin antibiotic, was evaluated for the treatment of lower respiratory tract infections. Intravenous cefotetan (2 g every 12 h) was administered for 4 to 8 days (mean, 5.8 days) to 56 hospitalized adult patients. Of the 41 evaluable patients, the clinical response was satisfactory in 38 (93%) and the bacteriological response was satisfactory in 36 (88%). The drug was well tolerated, and there were minimal complaints or changes in clinical laboratory values. From these preliminary results, cefotetan appears to be safe and effective for the treatment of lower respiratory tract infections.
ISSN:0305-7453
1460-2091
DOI:10.1093/jac/11.suppl_A.233